Express News | Merck’s Keytruda® (Pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, Iiia or Iiib Nsclc

Breakings44minutes ago

Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT NewswiresDec 14 02:53

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

BenzingaDec 14 01:15

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

BenzingaDec 13 20:50

Merck & Co. Gets Key European Backing for Welireg in Two Uses

WSJDec 13 20:30

Express News | Merck: Final Decision Is Expected in Q1 of 2025

BreakingsDec 13 20:05